Teclistamab

特立妥单抗

Report date: 2026/05/13 20:02:10
First In Class

Base Information

Drug NameTeclistamab
Drug Alias NameTeclistamab-CQYVTECAYLITECVAYLI泰立珂JNJ-64007957 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsB-cell maturation protein modulators
TargetsT cell surface glycoprotein CD3B-cell maturation protein
Therapy Area/IndicationsHematologic DiseasesSmoldering Multiple MyelomaMultiple Myeloma +[5] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryEU
Original Approved Date2022/08/23
Country/TerritoryCzechiaBelgiumCanada +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJohnson & Johnson Innovative MedicineGenmab A/S
China Registration ClassN/A

Develop Information

Active CompaniesFisher BioservicesJohnson & Johnson (China) Investment LtdJanssen-Cilag International Nv +[9] 
Inactive CompaniesStichting European Myeloma NetworkJohnson & Johnson Pharmaceutical LtdJanssen Pharmaceuticals Inc
Active IndicationsHematologic DiseasesSmoldering Multiple MyelomaMultiple Myeloma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL01FX24
Related LinksDrugBankKEGG